China is now the world's number two trial location. That is a worker story.

When people in this industry talk about offshoring, they usually mean data management moved to India or programming moved to eastern Europe. The bigger shift is happening one level up, in where the trials themselves run, and the public registry shows it plainly. China is now the second most common country for recruiting clinical trials in the world, and it is not close for third.

The ranking

Recruiting trials with at least one site in each country, from the public registry:

• United States: about 22,200
• China: about 11,700
• France: about 6,000
• Italy: about 4,200
• Canada: about 3,600
• Spain: about 3,100
• Germany: about 2,900
• United Kingdom: about 2,800
• South Korea: about 1,800
• Australia: about 1,800

Multi-country trials get counted in each country they touch, so these are site-presence counts rather than exclusive totals. Even so, the story is stark. China hosts nearly twice the recruiting-trial activity of France, the largest European country on the list, and roughly half the volume of the United States. A decade ago it would not have been in this conversation.

Why site location is a labor question

Trials are staffed near their sites. A study running in China is monitored by CRAs based in China, its data managed and often analyzed by teams in the region, at local wage levels. As more trial activity concentrates there, more of the monitoring and operational work concentrates there too. That is the same competitive pressure that reshaped programming and data management, now operating on the clinical operations layer.

For a US or European CRA, this does not mean the work disappears tomorrow. Trials still run where the patients and regulators are, and the US remains number one by a wide margin. But it does mean the global supply of people who can run a trial is growing fastest in a lower-cost region, and that supply shapes what sponsors are willing to pay everywhere. Wage pressure does not require your job to move. It only requires that a cheaper version of it exists at scale.

The nuance worth keeping

A large share of China's trials are domestically sponsored, run by Chinese pharma and biotech for the Chinese market, not Western programs relocated. So this is partly the rise of a separate, parallel industry rather than a direct transfer of Western jobs. Both things are true: some of it is genuine offshoring of global trials, and some of it is a new domestic industry that competes for the same global sponsor dollars and the same pool of experienced people.

What the registry cannot tell you

The registry shows where trials run. It cannot show you what a CRA in Shanghai earns versus one in Raleigh, or how much a sponsor's decision to run a study in China rather than the US actually saves. Those numbers decide whether this trend squeezes your pay, and they live only with the people doing the work in each place. The salary survey collects country alongside pay for exactly this reason. If you monitor or analyze trials anywhere, add your datapoint, and the global picture the registry can only sketch starts to fill in with real money.